Profilo
K Harold Fletcher is Secretary, Chief Legal & Strategy Officer at Celularity, Inc. since 2026.
Formerly, Mr. Fletcher was Chief Compliance Officer & Deputy General Counsel at Celularity, Inc. from 2021 to 2022, Senior Corporate Counsel at Kadmon Corp.
LLC from 2015 to 2018, and Associate at Sedgwick LLP from 2012 to 2015.
Education includes undergraduate studies at Rutgers State University of New Jersey and graduate studies at Seton Hall University.
Posizioni attive di K Fletcher
| Società | Posizione | Inizio |
|---|---|---|
| CELULARITY INC. | Consigliere Generale | 01/01/2026 |
Precedenti posizioni note di K Fletcher
| Società | Posizione | Fine |
|---|---|---|
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Consigliere Generale | 01/01/2018 |
Sedgwick LLP
Sedgwick LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Corporate Officer/Principal | 01/01/2015 |
| CELULARITY INC. | Responsabile della Conformità | 01/07/2022 |
Formazione di K Fletcher
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 5 |
|---|---|
Rutgers State University of New Jersey
Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seton Hall University
Seton Hall University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sedgwick LLP
Sedgwick LLP Miscellaneous Commercial ServicesCommercial Services Provides legal services | Commercial Services |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products | Health Technology |
Celularity, Inc.
Celularity, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage biotechnology company that discovers cancer sub-types and therapeutic options for cancer patients | Commercial Services |
















